melatonin and Neoplasms studies

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

Excerpt	Relevance	Reference
" The respective melatonin (n = 30) vs placebo (n = 30) outcomes were: incident delirium in 11/30 (36."	9.34	Melatonin to prevent delirium in patients with advanced cancer: a double blind, parallel, randomized, controlled, feasibility trial. ( Agar, M; Bush, SH; Currow, DC; Dasgupta, M; Lacaze-Masmonteil, N; Lawlor, PG; MacDonald, AR; McNamara-Kilian, MT; Momoli, F; Pereira, JL; Tierney, S, 2020)
" No significant differences between the placebo and melatonin periods were found for physical fatigue, secondary outcomes, or explorative outcomes."	9.20	Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double-blind placebo-controlled crossover trial. ( Andersen, L; Groenvold, M; Klee Olsen, M; Lindholm, H; Lund Rasmussen, C; Pedersen, L; Petersen, MA; Thit Johnsen, A; Villadsen, B, 2015)
"Prior studies have suggested that melatonin, a frequently used integrative medicine, can attenuate weight loss, anorexia, and fatigue in patients with cancer."	9.17	Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. ( Bruera, E; Del Fabbro, E; Dev, R; Hui, D; Palmer, L, 2013)
"Aging and advanced cancer are characterized by similar neuroendocrine and immune deficiencies; the most important of them consist of diminished nocturnal production of the pineal hormone melatonin (MLT) and decreased production of IL-2."	9.16	Cancer as the main aging factor for humans: the fundamental role of 5-methoxy-tryptamine in reversal of cancer-induced aging processes in metabolic and immune reactions by non-melatonin pineal hormones. ( Lissoni, P; Messina, G; Rovelli, F, 2012)
" In particular, thrombopoiesis has been proven to be stimulated by melatonin, and the pineal indole has been shown to be effective in the treatment of thrombocytopenia resulting from different causes."	9.09	Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia. ( Bonfanti, A; Bucovec, R; Fumagalli, L; Giani, L; Lissoni, P; Mandelli, A; Roselli, MG; Rovelli, F, 2001)
" In particular, the association with the pineal neurohormone melatonin (MLT) has been shown to cause tumour regressions in neoplasms that are generally non-responsive to IL-2 alone."	9.07	A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. ( Aldeghi, R; Ardizzoia, A; Barni, S; Brivio, F; Lissoni, P; Rescaldani, R; Ricci, G; Rovelli, F; Tancini, G; Tisi, E, 1994)
"The results of this systematic review indicated that co-administration of melatonin ameliorates the doxorubicin-induced cardiotoxicity."	9.05	The role of melatonin on doxorubicin-induced cardiotoxicity: A systematic review. ( Farhood, B; Haghi-Aminjan, H; Hooshangi Shayesteh, MR; Mortezaee, K; Najafi, M, 2020)
" Since there is a direct relationship between chronic inflammation and many emerging disorders like cancer, oral diseases, kidney diseases, fibromyalgia, gastrointestinal chronic diseases or rheumatics diseases, the aim of this review is to describe the use and role of melatonin, a hormone secreted by the pineal gland, that works directly and indirectly as a free radical scavenger, like a potent antioxidant."	8.91	Evaluating the Oxidative Stress in Inflammation: Role of Melatonin. ( Calpena, AC; Clares, B; Sánchez, A, 2015)
" Similarly, alterations in circadian rhythms as well as production of the pineal hormone melatonin have been linked to aging and cancer risk."	8.86	Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. ( Ahmad, N; Jung-Hynes, B; Reiter, RJ, 2010)
"It has been proposed that aging occurs because of a failure of the pineal gland to produce melatonin from serotonin each day beginning at sunset and throughout the night."	8.78	The role of melatonin and serotonin in aging: update. ( Grad, BR; Rozencwaig, R, 1993)
"On the basis of the demonstrated existence of immunoneuroendocrine interactions and on the previously observed synergistic action between the pineal hormone melatonin (MLT) and interleukin-2 (IL-2), we have designed a neuroimmunotherapeutic combination consisting of low-dose IL-2 and MLT in the treatment of advanced solid neoplasms."	7.68	Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results. ( Ardizzoia, A; Barni, S; Brivio, F; Conti, A; Lissoni, P; Maestroni, GJ; Rovelli, F; Tancini, G, 1993)
"Hypoxia has an important role in tumor progression via the up-regulation of growth factors and cellular adaptation genes."	6.72	Melatonin as a Therapeutic Agent for the Inhibition of Hypoxia-Induced Tumor Progression: A Description of Possible Mechanisms Involved. ( Akbarzadeh, M; Bastani, S; Farzane, A; Fattahi, A; Mollapour Sisakht, M; Nouri, M; Rastgar Rezaei, Y; Reiter, RJ, 2021)
"The possibility of natural cancer therapy has been recently suggested by advances in the knowledge of tumor immunobiology."	6.69	Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. ( Giani, L; Lissoni, P; Rovelli, F; Trabattoni, P; Zerbini, S, 1998)
"Hypotension is a frequent side-effect of cancer biotherapies with cytokines."	6.68	Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin. ( Ardizzoia, A; Barni, S; Braczkowski, R; Brivio, F; Lissoni, P; Maestroni, GJ; Pelizzoni, F; Pittalis, S; Tancini, G; Zubelewicz, B, 1996)
"Melatonin is a neurohormone secreted mainly by the pineal gland that controls circadian rhythm, which is primarily regulated by light."	6.52	Melatonin in aging women. ( Caglar, GS; Gursoy, AY; Kiseli, M, 2015)
"5-MTP blocks cancer cell migration and invasion in vitro and inhibits tumor growth and cancer metastasis in a xenograft model."	6.50	5-methoxyindole metabolites of L-tryptophan: control of COX-2 expression, inflammation and tumorigenesis. ( Chang, TC; Cheng, HH; Wu, KK, 2014)
"In particular, its use in cancer prevention, osteoporosis and, as an adjuvant to other therapies are discussed."	6.43	Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. ( Davis, VL; Doctor, JS; Radio, NM; Witt-Enderby, PA, 2006)
"Melatonin is a hormone secreted by the pineal gland in response to photoperiods and influences many important biological processes."	6.40	Melatonin, immune modulation and aging. ( Ardestani, SK; Elliott, KK; Inserra, PF; Liang, B; Molitor, M; Watson, RR; Zhang, Z, 1997)
" The respective melatonin (n = 30) vs placebo (n = 30) outcomes were: incident delirium in 11/30 (36."	5.34	Melatonin to prevent delirium in patients with advanced cancer: a double blind, parallel, randomized, controlled, feasibility trial. ( Agar, M; Bush, SH; Currow, DC; Dasgupta, M; Lacaze-Masmonteil, N; Lawlor, PG; MacDonald, AR; McNamara-Kilian, MT; Momoli, F; Pereira, JL; Tierney, S, 2020)
" No significant differences between the placebo and melatonin periods were found for physical fatigue, secondary outcomes, or explorative outcomes."	5.20	Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double-blind placebo-controlled crossover trial. ( Andersen, L; Groenvold, M; Klee Olsen, M; Lindholm, H; Lund Rasmussen, C; Pedersen, L; Petersen, MA; Thit Johnsen, A; Villadsen, B, 2015)
"Prior studies have suggested that melatonin, a frequently used integrative medicine, can attenuate weight loss, anorexia, and fatigue in patients with cancer."	5.17	Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. ( Bruera, E; Del Fabbro, E; Dev, R; Hui, D; Palmer, L, 2013)
"Aging and advanced cancer are characterized by similar neuroendocrine and immune deficiencies; the most important of them consist of diminished nocturnal production of the pineal hormone melatonin (MLT) and decreased production of IL-2."	5.16	Cancer as the main aging factor for humans: the fundamental role of 5-methoxy-tryptamine in reversal of cancer-induced aging processes in metabolic and immune reactions by non-melatonin pineal hormones. ( Lissoni, P; Messina, G; Rovelli, F, 2012)
" To find evidence related to the study objective, Iranian databases (SID, Magiran) and international databases (Google scholar, Web of Science, ProQuest, Medline via PubMed, Scopus) were searched using specified keywords (Melatonin, Sleep, insomnia, Cancer, Neoplasms, Carcinomas, Tumor, Carcinomatosis, Carcinomatoses, Sarcomas) from the beginning of the establishment of the mentioned databases until 31st December of 2020."	5.12	The effect of melatonin on sleep quality and insomnia in patients with cancer: a systematic review study. ( Bagheri-Nesami, M; Jafari-Koulaee, A, 2021)
" In particular, thrombopoiesis has been proven to be stimulated by melatonin, and the pineal indole has been shown to be effective in the treatment of thrombocytopenia resulting from different causes."	5.09	Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia. ( Bonfanti, A; Bucovec, R; Fumagalli, L; Giani, L; Lissoni, P; Mandelli, A; Roselli, MG; Rovelli, F, 2001)
" In particular, the association with the pineal neurohormone melatonin (MLT) has been shown to cause tumour regressions in neoplasms that are generally non-responsive to IL-2 alone."	5.07	A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. ( Aldeghi, R; Ardizzoia, A; Barni, S; Brivio, F; Lissoni, P; Rescaldani, R; Ricci, G; Rovelli, F; Tancini, G; Tisi, E, 1994)
"The results of this systematic review indicated that co-administration of melatonin ameliorates the doxorubicin-induced cardiotoxicity."	5.05	The role of melatonin on doxorubicin-induced cardiotoxicity: A systematic review. ( Farhood, B; Haghi-Aminjan, H; Hooshangi Shayesteh, MR; Mortezaee, K; Najafi, M, 2020)
" Since there is a direct relationship between chronic inflammation and many emerging disorders like cancer, oral diseases, kidney diseases, fibromyalgia, gastrointestinal chronic diseases or rheumatics diseases, the aim of this review is to describe the use and role of melatonin, a hormone secreted by the pineal gland, that works directly and indirectly as a free radical scavenger, like a potent antioxidant."	4.91	Evaluating the Oxidative Stress in Inflammation: Role of Melatonin. ( Calpena, AC; Clares, B; Sánchez, A, 2015)
"Melatonin, an indolamine derived from the amino-acid tryptophan, participates in diverse physiological functions and has great functional versatility related to the regulation of circadian rhythms and seasonal behaviour, sexual development, retinal physiology, tumour inhibition, as an antioxidant, immunomodulatory and anti-aging properties."	4.88	Melatonin, a natural programmed cell death inducer in cancer. ( de la Lastra, CA; Guerrero, JM; Packham, G; Sánchez-Hidalgo, M; Villegas, I, 2012)
" Similarly, alterations in circadian rhythms as well as production of the pineal hormone melatonin have been linked to aging and cancer risk."	4.86	Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. ( Ahmad, N; Jung-Hynes, B; Reiter, RJ, 2010)
" Persons who engage in nightshift work may exhibit altered nighttime melatonin levels and reproductive hormone profiles that could increase the risk of hormone-related diseases, including breast cancer."	4.83	Circadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in Seattle. ( Davis, S; Mirick, DK, 2006)
"It has been proposed that aging occurs because of a failure of the pineal gland to produce melatonin from serotonin each day beginning at sunset and throughout the night."	4.78	The role of melatonin and serotonin in aging: update. ( Grad, BR; Rozencwaig, R, 1993)
"Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy."	4.40	Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023)
"Clinical studies have shown that melatonin lowers the frequency of thrombocytopenia in patients with cancer undergoing radiotherapy or chemotherapy."	3.96	Melatonin protects against apoptosis of megakaryocytic cells via its receptors and the AKT/mitochondrial/caspase pathway. ( Chen, C; Chen, S; Chen, Y; He, Y; Li, L; Li, S; Wang, B; Xin, H; Xu, X; Yang, L; Yang, M; Ye, J; Zhang, C; Zhang, Q, 2020)
"The melatonin levels decreased with aging despite not reaching statistical significance, and the decrease was more evident in males than in females (40."	3.80	Melatonin and the Charlson Comorbidity Index (CCI): the Treviso Longeva (Trelong) study. ( Albani, D; Boldrini, P; Caberlotto, L; Di Giorgi, E; Durante, E; Flores-Obando, R; Forloni, G; Frigato, A; Gallucci, M; Mazzuco, S; Ongaro, F; Siculi, M; Taioli, E; Zanardo, A, 2014)
"MLT has been shown to exert anticancer activity through several biological mechanisms: antiproliferative action, stimulation of anticancer immunity, modulation of oncogene expression, and anti-inflammatory, anti-oxidant and anti-angiogenic effects."	3.80	Is there a role for melatonin in supportive care? ( Lissoni, P, 2002)
" Recent research has identified some of the likely molecular mediators of these potentially broad-ranging, health-enhancing and anti-aging effects; these include DHEA, interleukins -10 and -4 (IL-10, 1L-4), and especially melatonin."	3.73	From molecular biology to anti-aging cognitive-behavioral practices: the pioneering research of Walter Pierpaoli on the pineal and bone marrow foreshadows the contemporary revolution in stem cell and regenerative biology. ( Bushell, WC, 2005)
"The study seems to show a possible correlation between impaired rhythm of melatonin secretion and postoperative insomnia and postoperative sepsis in old patients undergoing surgery."	3.70	[The role of melatonin in the immediate postoperative period in elderly patients]. ( Barnabei, R; Cianca, G; Citone, G; Leardi, S; Necozione, S; Simi, M; Tavone, E, 2000)
"On the basis of the demonstrated existence of immunoneuroendocrine interactions and on the previously observed synergistic action between the pineal hormone melatonin (MLT) and interleukin-2 (IL-2), we have designed a neuroimmunotherapeutic combination consisting of low-dose IL-2 and MLT in the treatment of advanced solid neoplasms."	3.68	Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results. ( Ardizzoia, A; Barni, S; Brivio, F; Conti, A; Lissoni, P; Maestroni, GJ; Rovelli, F; Tancini, G, 1993)
"In order to investigate the pineal function and its relation with the hypophysis in human neoplasms, melatonin and GH serum levels were determined in 63 patients, 42 affected by solid tumours and 21 by lymphoma or leukaemia."	3.67	The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels. ( Bajetta, E; Bastone, A; di Bella, L; Esposti, D; Esposti, G; Lissoni, P; Mauri, R; Rovelli, F; Sala, R; Viviani, S, 1987)
"Melatonin was not associated with improved neurocognitive performance or sleep in our intent-to-treat analyses; however, a subset of survivors demonstrated a clinically significant treatment response."	3.11	A randomized double-blind placebo-controlled trial of the effectiveness of melatonin on neurocognition and sleep in survivors of childhood cancer. ( Brinkman, TM; Christensen, R; Greene, WL; Howell, CR; Hudson, MM; Kimberg, CI; Krull, KR; Li, C; Lubas, MM; Mandrell, BN; Ness, KK; Robison, LL; Srivastava, DK, 2022)
"Melatonin is a promising molecule for the treatment of breast cancer with antitumor effects on tumorigenesis and tumor progression."	3.01	Antitumor effect of melatonin on breast cancer in experimental models: A systematic review. ( do Carmo Neto, JR; Franco, PIR; Machado, JR; Miguel, MP; Milhomem, AC, 2023)
"During oncogenesis, cancer not only escapes the body's regulatory mechanisms, but also gains the ability to affect local and systemic homeostasis."	3.01	How cancer hijacks the body's homeostasis through the neuroendocrine system. ( Chen, JY; Raman, C; Slominski, AT; Slominski, RM, 2023)
"Melatonin is a safe molecule that affects almost all components of the tumor immune microenvironment and prevents them from being negatively affected by the tumor."	3.01	Cancer-associated immune cells and their modulation by melatonin. ( Asghari, MH; Fallah, M; Hekmatirad, S; Moloudizargari, M; Poortahmasebi, V; Rahimi, A, 2023)
"Cancer cachexia is a multi-organ syndrome with unintentional weight loss, sarcopenia, and systemic inflammation."	3.01	Relevance of Dietary Supplement Use in Gastrointestinal-Cancer-Associated Cachexia. ( Grundmann, O; Yoon, SL, 2023)
"Melatonin is a natural health product used for sleep disturbances."	2.90	Phase I dose-finding study for melatonin in pediatric oncology patients with relapsed solid tumors. ( Baruchel, S; Deyell, RJ; Johnston, DL; Morgenstern, D; Narendran, A; Nicksy, D; Samson, Y; Wu, B; Zupanec, S, 2019)
"As a cancer therapy adjuvant, melatonin could modulate TME oxidative stress levels and hypoxia, reverse pH gradient changes, reduce lipid peroxidation, and protect lipid raft compositions to suppress prion-mediated, non-Mendelian, heritable, but often reversible epigenetic adaptations that facilitate cancer heterogeneity, stemness, metastasis, and drug resistance."	2.82	Melatonin: Regulation of Prion Protein Phase Separation in Cancer Multidrug Resistance. ( Loh, D; Reiter, RJ, 2022)
"The exact mechanisms behind its anticancer effects remain unclear, and the specific characters impede its in vivo investigation."	2.82	Use of Melatonin in Cancer Treatment: Where Are We? ( Choi, WS; Wang, C; Wang, L, 2022)
"Melatonin is a natural body agent that has shown promising results for modulating tumour response to therapy and also alleviating normal tissue toxicity."	2.82	Modulation of the immune system by melatonin; implications for cancer therapy. ( Dakkali, MS; Jafarzadeh, E; Khodamoradi, E; Moazamiyanfar, R; Moslehi, M; Mouludi, K; Najafi, M; Rastegar-Pouyani, N; Rezaei, S; Taeb, S, 2022)
"Melatonin (MLT) is a hormone derived from tryptophan and secreted by the pineal gland."	2.82	Molecular basis of melatonin protective effects in metastasis: A novel target of melatonin. ( Asemi, Z; Homayoonfal, M; Maleki Dana, P; Sadoughi, F; Sharifi, M, 2022)
"Melatonin is a promising molecule which considered a differentiating agent in some cancer cells at both physiological and pharmacological concentrations."	2.82	Oncostatic activities of melatonin: Roles in cell cycle, apoptosis, and autophagy. ( Mir, SM; Qujeq, D; Rahimi, M; Reiter, RJ; Shahavi, MH; Targhazeh, N; Yousefi, T, 2022)
" In addition, the effects of different combinations of MLT dosage and duration, administration types and joint measures are worthy of further study."	2.82	Effect of melatonin on quality of life and symptoms in patients with cancer: a systematic review and meta-analysis of randomised controlled trials. ( Bu, X; Chen, H; Fan, R; Li, X; Tan, Y; Wang, T; Yang, S, 2022)
"Melatonin acts as an anticancer agent in breast tissue."	2.82	Melatonin: A Potential Antineoplastic Agent in Breast Cancer. ( Samanta, S, 2022)
"Adult patients with a cancer diagnosis who are admitted to the palliative care unit will be randomized into a treatment or placebo group."	2.82	The preventative role of exogenous melatonin administration to patients with advanced cancer who are at risk of delirium: study protocol for a randomized controlled trial. ( Agar, M; Bush, SH; Currow, DC; Lacaze-Masmonteil, N; Lawlor, PG; MacDonald, AR; McNamara-Kilian, MT; Momoli, F; Tierney, S, 2016)
"Hypoxia has an important role in tumor progression via the up-regulation of growth factors and cellular adaptation genes."	2.72	Melatonin as a Therapeutic Agent for the Inhibition of Hypoxia-Induced Tumor Progression: A Description of Possible Mechanisms Involved. ( Akbarzadeh, M; Bastani, S; Farzane, A; Fattahi, A; Mollapour Sisakht, M; Nouri, M; Rastgar Rezaei, Y; Reiter, RJ, 2021)
"Melatonin has several valuable biological activities such as antioxidant, anti-inflammation, antitumor, and antiaging activities."	2.72	Antitumor and Protective Effects of Melatonin: The Potential Roles of MicroRNAs. ( Ahmadi, Z; Ashrafizadeh, M; Jamialahmadi, T; Sahebkar, A; Sathyapalan, T; Yaribeygi, H, 2021)
"Melatonin has been reported to present numerous antitumor effects, which result in a reduced cell growth."	2.72	Regulation of cancer cell glucose metabolism is determinant for cancer cell fate after melatonin administration. ( Antolín, I; Duarte-Olivenza, C; Herrera, F; Martín, V; Puente-Moncada, N; Reiter, RJ; Rodríguez, C; Rodríguez-Blanco, J; Sánchez-Sánchez, AM; Turos-Cabal, M, 2021)
"GPCR alterations associated with cancer development represent significant challenges for the discovery and the advancement of targeted therapeutics."	2.72	Two neuroendocrine G protein-coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives. ( Brenna, C; Conti, I; Costanzi, E; Laface, I; Neri, LM; Simioni, C; Varano, G, 2021)
"With regard to cancer, melatonin's potential to suppress cancer initiation, progression, angiogenesis and metastasis as well as sensitizing malignant cells to conventional chemo- and radiotherapy are among its most interesting effects."	2.72	Therapeutic targets of cancer drugs: Modulation by melatonin. ( Asghari, MH; Fallah, M; Hekmatirad, S; Moloudizargari, M; Moradkhani, F; Reiter, RJ, 2021)
"Melatonin is a glycolytic which converts diseased cells to the healthier phenotype."	2.72	Anti-Warburg Effect of Melatonin: A Proposed Mechanism to Explain its Inhibition of Multiple Diseases. ( Reiter, RJ; Rosales-Corral, S; Sharma, R, 2021)
"Melatonin is a pleotropic molecule with numerous biological activities."	2.72	Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities. ( Abuawad, A; Alsayed, AR; Daoud, S; Mahmod, AI; Talib, WH, 2021)
"The evidence indicates that solid tumors may redirect their metabolic phenotype from the pathological Warburg-type metabolism during the day to the healthier mitochondrial oxidative phosphorylation on a nightly basis."	2.72	Part-time cancers and role of melatonin in determining their metabolic phenotype. ( Chuffa, LGA; Martin, V; Reiter, RJ; Rodriguez, C; Rosales-Corral, S; Sharma, R; Zuccari, DAPC, 2021)
"The possibility of natural cancer therapy has been recently suggested by advances in the knowledge of tumor immunobiology."	2.69	Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. ( Giani, L; Lissoni, P; Rovelli, F; Trabattoni, P; Zerbini, S, 1998)
"26 Italian hospitals specialising in cancer treatment."	2.69	Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): results of phase II trials in Italy. Italian Study Group for the Di Bella Multitherapy Trails. ( , 1999)
"This study shows that cancer neuroimmunotherapy with low-dose IL-2 and the pineal hormone melatonin may prolong survival time and improve the quality of life of patients with metastatic solid tumours who do not respond to conventional therapies."	2.68	A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour. ( Ardizzoia, A; Barni, S; Cazzaniga, M; Fossati, V; Frigerio, F; Lissoni, P; Tancini, G, 1995)
"Hypotension is a frequent side-effect of cancer biotherapies with cytokines."	2.68	Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin. ( Ardizzoia, A; Barni, S; Braczkowski, R; Brivio, F; Lissoni, P; Maestroni, GJ; Pelizzoni, F; Pittalis, S; Tancini, G; Zubelewicz, B, 1996)
"Lung cancer patients were treated with cisplatin and etoposide, breast cancer patients with mitoxantrone, and gastrointestinal tract tumor patients with 5-fluorouracil plus folates."	2.68	Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. ( Ardizzoia, A; Barni, S; Conti, A; Lissoni, P; Maestroni, G; Paolorossi, F; Tancini, G, 1997)
"Melatonin has a variety of biological effects, including inhibition of tumor metastasis, stabilizing atherosclerotic plaques, and the regulation of seasonal reproductive rhythms, etc."	2.66	Role of melatonin in controlling angiogenesis under physiological and pathological conditions. ( Chen, Y; Ma, Q; Reiter, RJ, 2020)
"Melatonin has the ability to intervene in the initiation, progression and metastasis of some experimental cancers."	2.66	Melatonin inhibits Warburg-dependent cancer by redirecting glucose oxidation to the mitochondria: a mechanistic hypothesis. ( de Almeida Chuffa, LG; Ma, Q; Reiter, RJ; Rorsales-Corral, S; Sharma, R, 2020)
"Melatonin is a physiological hormone produced by the pineal gland."	2.66	Targeting cancer stem cells by melatonin: Effective therapy for cancer treatment. ( Akbarzadeh, M; Hajazimian, S; Hemati, S; Isazadeh, A; Maroufi, NF; Nouri, M; Pouremamali, F; Rashidi, MR; Seraji, N; Taefehshokr, S; Vahedian, V; Zahedi, M, 2020)
"Melatonin is a potent antioxidant and antiageing molecule, is nontoxic, and enhances the efficacy and reduces the side effects of chemotherapy."	2.66	Utilizing Melatonin to Alleviate Side Effects of Chemotherapy: A Potentially Good Partner for Treating Cancer with Ageing. ( Di, S; Han, J; Li, W; Li, X; Liu, D; Ma, Z; Reiter, RJ; Xu, L; Yan, X; Zhang, J; Zhang, X, 2020)
"Melatonin is an amphipathic indolamine molecule ubiquitously present in all organisms ranging from cyanobacteria to humans."	2.66	Melatonin: an endogenous miraculous indolamine, fights against cancer progression. ( Samanta, S, 2020)
"Melatonin is a ubiquitous molecule with a broad spectrum of functions including widespread anti-cancer activities."	2.66	A meta-analysis of microRNA networks regulated by melatonin in cancer: Portrait of potential candidates for breast cancer treatment. ( Carvalho, RF; Chuffa, LGA; Cury, SS; Jardim-Perassi, BV; Justulin, LA; Reiter, RJ; Seiva, FRF; Zuccari, DAPC, 2020)
"Melatonin is a ubiquitous indole amine that plays a fundamental role in the regulation of the biological rhythm."	2.66	Immunoregulatory role of melatonin in cancer. ( Asghari, MH; Asghari, N; Fallah, M; Heidari Khoei, H; Moloudizargari, M; Moradkhani, F, 2020)
"Melatonin is a natural agent with anti-cancer functions that has also been suggested as an adjuvant in combination with cancer therapy modalities such as chemotherapy, radiotherapy, immunotherapy and tumor vaccination."	2.61	Boosting immune system against cancer by melatonin: A mechanistic viewpoint. ( Farhood, B; Mirtavoos-Mahyari, H; Mortezaee, K; Motevaseli, E; Musa, AE; Najafi, M; Potes, Y; Shabeeb, D, 2019)
"It is estimated that more than half of cancer patients undergo radiotherapy during the course of their treatment."	2.61	Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization. ( Farhood, B; Goradel, NH; Khanlarkhani, N; Mirtavoos-Mahyari, H; Mortezaee, K; Motevaseli, E; Musa, AE; Najafi, M; Nashtaei, MS; Salehi, E; Shabeeb, D, 2019)
"Studies have recruited heterogeneous cancer patient populations in late disease stages, and many had issues with accrual and attrition."	2.61	Anti-cytokines in the treatment of cancer cachexia. ( Prado, BL; Qian, Y, 2019)
"Melatonin is a multifunctional hormone that has long been known for its antitumoral effects."	2.61	Adjuvant chemotherapy with melatonin for targeting human cancers: A review. ( Farhood, B; Hashemi Goradel, N; Khanlarkhani, N; Mortezaee, K; Najafi, M; Namjoo, Z; Nashtaei, MS; Salehi, E, 2019)
"Evidence suggests that genomic instability is responsible for cancer incidence after exposure to carcinogenic agents, and increases the risk of secondary cancers following treatment with radiotherapy or chemotherapy."	2.61	Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment. ( Farhood, B; Goradel, NH; Khanlarkhani, N; Mortezaee, K; Najafi, M; Sahebkar, A, 2019)
"Melatonin is a beneficial agent in the treatment of inflammatory and immune disorders."	2.61	Melatonin, a toll-like receptor inhibitor: Current status and future perspectives. ( Asemi, Z; Azami, A; Gholami, MS; Mobini, M; Reiter, RJ; Tamtaji, OR, 2019)
"Melatonin is a effective antioxidant and circadian pacemaker."	2.61	The potential utility of melatonin in the treatment of childhood cancer. ( Chao, YH; Reiter, RJ; Su, SC; Wu, KH; Yang, SF; Yeh, CM, 2019)
"Melatonin is a potent natural antioxidant and anti-inflammatory agent that protects against toxic side effects of radiation and chemotherapy."	2.61	Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review. ( Ahmadi, A; Farhood, B; Mortezaee, K; Musa, AE; Najafi, M; Potes, Y; Shabeeb, D, 2019)
"Melatonin can variably affect cancer pathology via targeting several key aspects of any neoplastic condition, including the very onset of carcinogenesis as well as tumor growth, differentiation, and dissemination."	2.58	Does the use of melatonin overcome drug resistance in cancer chemotherapy? ( Abdollahi, M; Asghari, MH; Fallah, M; Ghobadi, E; Moloudizargari, M, 2018)
"Melatonin is a natural indoleamine produced by the pineal gland that has many functions, including regulation of the circadian rhythm."	2.58	Melatonin and Cancer Hallmarks. ( Talib, WH, 2018)
"A link between cancer and inflammation and/or metabolic disorders has been well established and the therapy of these conditions with so-called pleiotropic drugs, which include non-steroidal anti-inflammatory drugs, statins and peroral antidiabetics, modulates a cancer risk too."	2.58	Melatonin May Increase Anticancer Potential of Pleiotropic Drugs. ( Bojková, B; Kajo, K; Kubatka, P; Qaradakhi, T; Zulli, A, 2018)
"This review summarized the anticancer efficacy of melatonin, based on the results of epidemiological,experimental and clinical studies, and special attention was paid to the mechanisms of action."	2.55	Melatonin for the prevention and treatment of cancer. ( Li, HB; Li, S; Li, Y; Meng, X; Xu, DP; Zhang, JJ; Zhou, Y, 2017)
"While the emphasis of melatonin/cancer research has been on the role of the indoleamine in restraining breast cancer, this is changing quickly with many cancer types having been shown to be susceptible to inhibition by melatonin."	2.55	Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis. ( Acuna-Castroviejo, D; Qin, L; Reiter, RJ; Rosales-Corral, SA; Tan, DX; Xu, K; Yang, SF, 2017)
"Premature ovarian failure is one of the side effects of chemotherapy in pre-menopausal cancer patients."	2.55	Melatonin and Fertoprotective Adjuvants: Prevention against Premature Ovarian Failure during Chemotherapy. ( Choi, Y; Hong, K; Jang, H, 2017)
"Both obesity and breast cancer are already recognized worldwide as the most common syndromes in our modern society."	2.55	Artificial light-at-night - a novel lifestyle risk factor for metabolic disorder and cancer morbidity. ( Haim, A; Zubidat, AE, 2017)
"The incidence of both type 2 diabetes (T2DM) and cancer is increasing worldwide, making these diseases a global health problem along with increasing healthcare expenditures."	2.55	Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer. ( Cypryk, K; Krawczyk, M; Wojcik, M; Wojcik, P; Wozniak, LA, 2017)
"Patients with cancer frequently experience unintended weight loss due to gastrointestinal (GI) dysfunction caused by the malignancy or treatment of the malignancy."	2.55	Cancer Cachexia: Cause, Diagnosis, and Treatment. ( Mattox, TW, 2017)
"Melatonin has shown the potential to inhibit growth of different tumors, both in vitro and in vivo."	2.55	Melatonin with adenosine solubilized in water and stabilized with glycine for oncological treatment - technical preparation, effectivity and clinical findings. ( Di Bella, G; Di Bella, L; Gualano, L, 2017)
"Inflammation is mediated by various genes and cytokines related to immune system responses caused by massive cell death following radiotherapy."	2.55	Melatonin as an anti-inflammatory agent in radiotherapy. ( Motevaseli, E; Najafi, M; Rezaeyan, AH; Rezapoor, S; Salajegheh, A; Shirazi, A, 2017)
"Melatonin is a regulator of haemopoiesis and modifies various cells and cytokines of the immune system."	2.52	[The influence of melatonin on the immune system and cancer]. ( Claësson, MH; Vinther, AG, 2015)
"Melatonin is a neurohormone secreted mainly by the pineal gland that controls circadian rhythm, which is primarily regulated by light."	2.52	Melatonin in aging women. ( Caglar, GS; Gursoy, AY; Kiseli, M, 2015)
"5-MTP blocks cancer cell migration and invasion in vitro and inhibits tumor growth and cancer metastasis in a xenograft model."	2.50	5-methoxyindole metabolites of L-tryptophan: control of COX-2 expression, inflammation and tumorigenesis. ( Chang, TC; Cheng, HH; Wu, KK, 2014)
"Melatonin plays an important role in cancer (tumor growth and metastasis) through different pathways and may have therapeutic significance."	2.50	Melatonin and cancer. ( Gheorghe, DC; Popescu, CR; Zamfir Chiru, AA, 2014)
"This is as true of cancer as it is of the development of cardiovascular, autoimmune, and neurodegenerative disease, in all of these immunological surveillance break downs, leading to an unraveling of the neuroimmunoendocrine process that inhibits proliferation of preneoplastic and neoplastic cells already existing in the body."	2.49	Cancer and the endogenous "pineal clock": a means of early diagnosis and successful treatment as well as prevention of cancers. ( Pierpaoli, W, 2013)
"sleep and mood), immune function, cancer initiation and growth, as well as the correlation between melatonin levels and cancer risk, are hereinafter recorded and summarized."	2.49	Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks. ( Antoniello, N; Faliva, MA; Perna, S; Rondanelli, M, 2013)
"Melatonin has both the ability to induce intrinsic apoptosis in tumor cells while it inhibits it in non-tumor cells."	2.48	Melatonin: the smart killer: the human trophoblast as a model. ( Lacasse, AA; Lanoix, D; Reiter, RJ; Vaillancourt, C, 2012)
"MLT may benefit cancer patients who are also receiving chemotherapy, radiotherapy, supportive therapy, or palliative therapy by improving survival and ameliorating the side effects of chemotherapy."	2.48	Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. ( Fritz, H; Kennedy, DA; Mills, E; Seely, AJ; Seely, D; Tsui, T; Wu, P, 2012)
"The rationale for cancer neuroimmunotherapy consists of the possibility to enhance the efficacy of the various immunotherapeutic strategies by a concomitant administration of antitumor cytokines (namely IL-2), in addition to neuroendocrine endogenous molecules (namely the pineal indole hormones), able to stimulate the anticancer immunoresponse by amplifying the anticancer reaction and/or by counteracting the generation of immunosuppressive events."	2.48	Principles of psychoneuroendocrinoimmunotherapy of cancer. ( Lissoni, P; Rovelli, F, 2012)
" No severe adverse events were reported."	2.48	The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. ( Ai, F; Dong, TF; Duan, CH; Fu, QL; Jin, BZ; Lu, YZ; Wang, YM, 2012)
"Melatonin has revealed itself to be a pleiotropic and multitasking molecule."	2.48	Role of melatonin in cancer treatment. ( Arias-Santiago, S; Cutando, A; DE Diego, RG; DE Vicente, J; López-Valverde, A, 2012)
" The recognition of the periodicity of biological processes makes the optimal dosing of certain drugs feasible."	2.48	[Physiological and pathophysiological role of the circadian clock system]. ( Halmos, T; Suba, I, 2012)
"The increased cancer risk has been reported in nurses, radio-telephone operators, flight attendants, and women employed in the enterprises, in which 60% of employees work at night."	2.47	[Night shift work and cancer risk: a literature review]. ( Brudnowska, J; Pepłońska, B, 2011)
"Melatonin is a natural substance ubiquitous in distribution and present in almost all species ranging from unicellular organisms to humans."	2.47	Melatonin, immune function and cancer. ( Bhatnagar, KP; Brzezinski, A; Cardinali, DP; Pandi-Perumal, SR; Srinivasan, V, 2011)
"Melatonin has been also used as a complementary treatment in anaesthesia, hemodialysis, in vitro fertilization and neonatal care."	2.46	Clinical uses of melatonin: evaluation of human trials. ( Mediavilla, MD; Reiter, RJ; Sánchez-Barceló, EJ; Tan, DX, 2010)
"In pathological processes such as cancer, increased migration occurs in invasive cells driven by the formation of polarized and differential microfilament phenotypes."	2.45	Melatonin modulates microfilament phenotypes in epithelial cells: implications for adhesion and inhibition of cancer cell migration. ( Benítez-King, G; Ramírez-Rodriguez, G; Soto-Vega, E, 2009)
"Patients with advanced lung cancer suffering greater circadian activity/sleep cycle disruption suffer greater interference with function, greater anxiety and depression, poorer nighttime sleep, greater daytime fatigue, and poorer quality of life than comparable patients who maintain good circadian integration."	2.45	Circadian clock manipulation for cancer prevention and control and the relief of cancer symptoms. ( Ansell, C; Braun, D; Du-Quiton, J; Ferrans, C; Grutsch, J; Hrushesky, WJ; Kidder, S; Levin, R; Lis, C; Oh, EY; Quiton, DF; Reynolds, J; Wood, P; Yang, X, 2009)
"This high cancer frequency is not explained by any of the conventional causes."	2.45	Light-mediated perturbations of circadian timing and cancer risk: a mechanistic analysis. ( Erren, TC; Fuentes-Broto, L; Paredes, SD; Reiter, RJ; Tan, DX, 2009)
"Likewise, in experimental animals, cancer growth is exaggerated when the animals are repeatedly phase advanced (as occurs during easterly flights) or exposed to light at night."	2.44	Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. ( Erren, TC; Korkmaz, A; Manchester, LC; Piekarski, C; Reiter, RJ; Tamura, H; Tan, DX, 2007)
"Melatonin is a phylogenetically well-preserved molecule with diverse physiological functions."	2.44	Therapeutic actions of melatonin in cancer: possible mechanisms. ( Cardinali, DP; Pandi-Perumal, SR; Spence, DW; Srinivasan, V; Trakht, I, 2008)
"Melatonin plays a role in maintaining sleep-wake rhythms; supplementation may help to regulate sleep disturbance that occur with jet lag, rotating shift-work and depression."	2.44	Neurobiological effects of melatonin as related to cancer. ( Hoang, BX; Levine, SA; Pham, PT; Shaw, DG, 2007)
"Melatonin is a small lipophile molecule, essentially secreted by pineal gland."	2.43	[Therapeutic potential of melatonin in cancer treatment]. ( Abrial, C; Chevrier, R; Chollet, P; Curé, H; Gachon, F; Kwiatkowski, F, 2005)
"Stress then seems enable to increase cancer risk through its negative impact on HHS and HP axis and therefore on immunity."	2.43	[Stress, cancer and circadian rhythm of melatonin]. ( Abrial, C; Chevrier, R; Chollet, P; Curé, H; Gachon, F; Kwiatkowski, F, 2005)
"All trials included solid tumor cancers."	2.43	Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. ( Guyatt, G; Mills, E; Seely, D; Wu, P, 2005)
"Evidence indicates that melatonin's anticancer effects are exerted via inhibition of cell proliferation and a stimulation of differentiation and apoptosis."	2.43	Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. ( Blask, DE; Dauchy, RT; Sauer, LA, 2005)
"Melatonin also has strong antioxidant properties (stronger than those of vitamin E), and an oncostatic action."	2.43	[Melatonin: what for?]. ( Touitou, Y, 2005)
"Breast cancer is the oncological disease entity whose relationship to circadian rhythm fluctuations has perhaps been most extensively studied."	2.43	Light during darkness and cancer: relationships in circadian photoreception and tumor biology. ( Blask, DE; Brainard, GC; Jasser, SA, 2006)
"breast cancer in industrialized countries."	2.43	The anti-tumor activity of pineal melatonin and cancer enhancing life styles in industrialized societies. ( Bartsch, C; Bartsch, H, 2006)
" Moreover, in animal models, interventions that increase the bioavailability of melatonin appears to increase the severity of parkinsonian symptoms, whereas reduction in melatonin by pinealectomy or exposure to bright light can enhance recovery from parkinsonisms symptoms."	2.43	Circulating melatonin levels: possible link between Parkinson's disease and cancer risk? ( Chen, H; Ritz, B; Schernhammer, E, 2006)
"In particular, its use in cancer prevention, osteoporosis and, as an adjuvant to other therapies are discussed."	2.43	Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. ( Davis, VL; Doctor, JS; Radio, NM; Witt-Enderby, PA, 2006)
"Melatonin is a neuroendocrine hormone secreted by the pineal gland to transduce the body's circadian rhythms."	2.43	Melatonin in pathogenesis and therapy of cancer. ( Ahuja, YR; Lakshmi, NK; Ravindra, T, 2006)
"Melatonin is a natural compound synthesized by a variety of organs."	2.42	Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. ( Lopez-Burillo, S; Mayo, JC; Reiter, RJ; Rodriguez, C; Sainz, RM; Tan, DX, 2003)
"Cancer is the second leading cause of death in industrialised countries like the United States, where a significant proportion of workers engage in shift work, making a hypothesised relation between light exposure at night and cancer risk relevant."	2.42	Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels? ( Schernhammer, ES; Schulmeister, K, 2004)
"The ability of LA to promote cancer progression is accomplished by its intracellular metabolism to 13-hydroxyoctadecadienoic acid (13-HODE) which amplifies the activity of the epidermal growth factor receptor/mitogen-activated protein kinase pathway leading to cell proliferation."	2.41	Light during darkness, melatonin suppression and cancer progression. ( Blask, DE; Brainard, GC; Dauchy, RT; Krause, JA; Sauer, LA, 2002)
"Melatonin was also shown to inhibit the growth of several animal and human tumor cell lines in vitro."	2.41	Oncostatic action of melatonin: facts and question marks. ( Karasek, M; Pawlikowski, M; Winczyk, K, 2002)
"Melatonin is depressed in patients with cancers of different origins during the phase of primary tumour growth whereas a normal or sometimes elevated pineal melatonin secretory activity is found during early stages of tumour development or when recidivations arise."	2.41	Melatonin in clinical oncology. ( Bartsch, C; Bartsch, H; Karasek, M, 2002)
"Some human and murine in vitro cancer cell lines are inhibited by physiological concentrations of melatonin, but the majority of the tested cell lines is resistant to melatonin or can be inhibited at pharmacological doses only."	2.40	[Significance of melatonin in malignant diseases]. ( Bartsch, C; Bartsch, H, 1997)
"Melatonin is a hormone secreted by the pineal gland in response to photoperiods and influences many important biological processes."	2.40	Melatonin, immune modulation and aging. ( Ardestani, SK; Elliott, KK; Inserra, PF; Liang, B; Molitor, M; Watson, RR; Zhang, Z, 1997)
"Melatonin has been used successfully to treat jet lag and some circadian-based sleep disorders."	2.40	[Melatonin and its wide-spectrum effects: use of melatonin in the treatment of tumors]. ( Solár, P, 1999)
"(2) Only its use in jet lag, sleep disorders and advanced cancer has been tested clinically (albeit scantily)."	2.40	Melatonin: interesting, but not miraculous. ( , 1998)
"Melatonin has immunoenhancing properties and it is able to counteract the immunodepression induced by acute stress, drug treatment (i."	2.39	The clinical neuroimmunotherapeutic role of melatonin in oncology. ( Conti, A; Maestroni, GJ, 1995)
"Melatonin is a molecule with different antitumor actions in breast cancer and has been described as an inhibitor of vascular endothelial growth factor (VEGF)."	1.91	Development of in vitro and in vivo tools to evaluate the antiangiogenic potential of melatonin to neutralize the angiogenic effects of VEGF and breast cancer cells: CAM assay and 3D endothelial cell spheroids. ( Alba, E; Aranega-Martín, L; Boutriq, S; Castellano-Castillo, D; González-González, A; Laborda-Illanes, A; Peralta-Linero, J; Plaza-Andrades, I; Queipo-Ortuño, MI; Sánchez-Alcoholado, L, 2023)
"Melatonin was found to directly and indirectly inhibit tumor progression."	1.91	Melatonin blunts the tumor-promoting effect of cancer-associated fibroblasts by reducing IL-8 expression and reversing epithelial-mesenchymal transition. ( Bai, X; Chen, H; Dong, J; Li, H; Liao, H; Si, H; Song, J; Wang, J, 2023)
" CP was given once intraperitoneally (10 mg/kg,) eliciting acute kidney injury as assured by several adverse histological changes; glomerulopathy, tubulopathy, and vasculopathy, an inflammatory response including elevated TNF-α, IL-6, and IL-1β."	1.72	TGF-β1, NAG-1, and antioxidant enzymes expression alterations in Cisplatin-induced nephrotoxicity in a rat model: Comparative modulating role of Melatonin, Vit. E and Ozone. ( Abd El-Emam, MM; Abdel-Rahman Mohamed, A; Bin Emran, T; El-Shetry, ES; Khater, SI; Metwally, MMM; Mostafa-Hedeab, G; Nassan, MA, 2022)
"In fact, MLT is an anti-cancer agent that has various functions in inhibiting cancer cell proliferation, inducing apoptosis, and suppressing metastasis."	1.72	Melatonin as an adjuvant treatment modality with doxorubicin. ( Asemi, Z; Heidar, Z; Maleki Dana, P; Mirzamoradi, M; Mohammadi, S; Reiter, RJ; Sadoughi, F, 2022)
"We also examined the effects of MMT on insomnia, fatigue, depression, quality of life and actigraphy."	1.62	Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy. ( Balachandran, D; Bruera, E; Carmack, C; Delgado, M; Eng, C; Guzman Gutierrez, D; Hess, KR; Lim, B; Lu, Z; Ochoa, J; Park, M; Raznahan, M; Williams, JL; Yennurajalingam, S, 2021)
"The ability of melatonin to switch cancer cells as well as other diseased cells, for example, Alzheimer disease, fibrosis, hyperactivation of macrophages, etc, from aerobic glycolysis to mitochondrial oxidative phosphorylation may be a basic protective mechanism to reduce pathologies."	1.62	Switching diseased cells from cytosolic aerobic glycolysis to mitochondrial oxidative phosphorylation: A metabolic rhythm regulated by melatonin? ( Ma, Q; Reiter, RJ; Sharma, R, 2021)
"Phenylarsine oxide (PAO) has anticancer potential but it is considered as a toxic agent."	1.56	Melatonin triggers the anticancer potential of phenylarsine oxide via induction of apoptosis through ROS generation and JNK activation. ( Cui, ZG; Feng, QW; Inadera, H; Li, JL; Li, ML; Li, YL; Muhammad, JS; Sun, L; Zakki, SA, 2020)
"RNA-seq data from The Cancer Genome Atlas (TCGA) of 14 solid tumors representing 6658 human samples were analyzed."	1.51	Pan-cancer genomic analyses reveal prognostic and immunogenic features of the tumor melatonergic microenvironment across 14 solid cancer types. ( Chen, L; Chen, YP; Lin, AH; Lv, JW; Ma, J; Mao, YP; Reiter, RJ; Sun, Y; Wang, ZX; Zheng, ZQ; Zhou, GQ, 2019)
"Melatonin has been shown to decrease the toxic effects of cisplatin due to its antioxidant activity, and could increase the efficacy of cancer chemotherapy."	1.51	Protective Effect of Melatonin on Cisplatin-induced Ototoxicity in Rats. ( DE Araujo, JG; Kückelhaus, SAS; Lauand, L; Sampaio, ALL; Serra, LSM, 2019)
"Docetaxel (DTX) has been used in cancer treatments for several decades, but it results in many adverse apoptotic effects through excessive production of reactive oxygen species (ROS) in some tissue including the kidney and testes."	1.51	Treatment with melatonin and selenium attenuates docetaxel-induced apoptosis and oxidative injury in kidney and testes of mice. ( Baş, E; Nazıroğlu, M, 2019)
"Melatonin-stimulated an increase in p21 which was correlated with a pronounced nuclear translocation of thioredoxin 1 and thioredoxin reductase 1, both of which are known to induce p21 via promoting p53 trans-activation."	1.51	Melatonin and (-)-Epigallocatechin-3-Gallate: Partners in Fighting Cancer. ( He, Y; Reiter, RJ; Wu, X; Yang, CS; Zhang, J; Zhang, K; Zhang, L; Zhao, G, 2019)
"The degree of complexity of a cancer system could be vast involving multiple endogenous and exogenous agents interacting with the over 10 trillion cells comprising the body."	1.48	A complex systems approach to cancer prevention. ( Jupp, PW, 2018)
"The association between shift work and cancer, which is thought to be mediated by effects on circulating melatonin levels, may be modified by chronotype (ie, the inherent preference for activity in the morning or the evening); however, few studies have examined the potential impact of chronotype on the carcinogenic effects of shift work."	1.40	The impact of chronotype on melatonin levels among shift workers. ( Bhatti, P; Davis, S; Mirick, DK, 2014)
"Melatonin production was estimated with the excretion of urinary 6-sulfatoxymelatonin (aMT6s)."	1.40	Progressive decrease of melatonin production over consecutive days of simulated night work. ( Dumont, M; Paquet, J, 2014)
"Night shift work is associated with cancer among men, but the biologic mechanism is unclear."	1.39	Night shift work and levels of 6-sulfatoxymelatonin and cortisol in men. ( Bhatti, P; Chen, C; Davis, S; Mirick, DK; Nordt, F; Stanczyk, FZ, 2013)
"Melatonin production was estimated with the excretion of urinary 6-sulfatoxymelatonin (aMT6s), and light exposure was measured with an ambulatory photometer."	1.38	Melatonin production and light exposure of rotating night workers. ( Cadieux-Viau, R; Dumont, M; Lanctôt, V; Paquet, J, 2012)
"Melatonin treatment is able to stimulate production of intracellular reactive oxygen species (ROS), as revealed by the increase in rhodamine-123 fluorescence, which was associated with significant cytotoxicity and activation of caspase activities."	1.37	Pro-oxidant effect of melatonin in tumour leucocytes: relation with its cytotoxic and pro-apoptotic effects. ( Barriga, C; Bejarano, I; Espino, J; Pariente, JA; Reiter, RJ; Rodríguez, AB, 2011)
"Tumors are commonly found during senescence of several strains of mice."	1.37	Extended exposure to dietary melatonin reduces tumor number and size in aged male mice. ( Bondy, SC; Sharman, EH; Sharman, KG, 2011)
"Melatonin is an endogenous indolamine, classically known as a light/dark regulator."	1.37	Intracellular redox state as determinant for melatonin antiproliferative vs cytotoxic effects in cancer cells. ( Antolín, I; Casado-Zapico, S; García-Santos, G; Martín, V; Rodriguez, C; Rodríguez-Blanco, J; Sánchez-Sánchez, AM; Suarez-Garnacho, S, 2011)
"Melatonin treatment caused a significant reduction in the weight of tumors and reduced metastases when compared with the control group."	1.32	Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. ( Calvo, JR; Guerrero, JM; Leon-Blanco, MM; Pozo, D; Reiter, RJ, 2003)
"Contrary to the paradigm that cancer incidence increases indefinitely with age, significant data now suggest cancer incidence may markedly reduce beyond age 80 years for humans and beyond 800 days for mice, and is not inevitable."	1.31	A quantitative model of cellular senescence influence on cancer and longevity. ( Pompei, F; Wilson, R, 2002)
"Twenty tumors (ovarian, renal, colorectal, gastric, skin, testicular, thyroid, adrenal gland, endometrial, cervical uterus ones, and melanoma) were isolated from patients at surgery."	1.31	[Effects of biorhythm regulator melatonin on DNA synthesis in short-term cultures of human malignant tumors]. ( Bodrova, NB; Nikolaeva, TG; Riabykh, TP, 2000)
"Melatonin is a well-known antioxidant, free radical scavenger, and oncostatic agent."	1.31	Melatonin attenuates estradiol-induced oxidative damage to DNA: relevance for cancer prevention. ( Burkhardt, S; Gitto, E; Karbownik, M; Lewiñski, A; Reiter, RJ; Tan, DX, 2001)
"Melatonin is a hormone primarily produced by the pineal gland at night and is suppressed by exposure to light."	1.30	Reduced cancer incidence among the blind. ( Ahlbom, A; Feychting, M; Osterlund, B, 1998)
"Low melatonin levels seem to parallel cancer growth."	1.29	Hepatic hydroxylation of melatonin in the rat is induced by phenobarbital and 7,12-dimethylbenz[a]anthracene--implications for cancer etiology. ( Bartsch, C; Bartsch, H; Lippert, TH; Mecke, D; Praast, G, 1995)
"Although few cancer experiments have been done yet, there are a number of biological effects of EMF reported in the literature that might provide bases for designing cancer experiments and epidemiologic studies."	1.29	Biologically based epidemiological studies of electric power and cancer. ( Stevens, RG, 1993)
"At present, cancer is responsible for almost half of all deaths among women 45-64 years of age, and about 30% of all deaths among men in the same age group (1)."	1.28	Why the incidence of cancer is increasing: the role of 'light pollution'. ( Feuer, G; Kerenyi, NA; Pandula, E, 1990)
"Melatonin was enhanced after CDDP and CMF, and cortisol decreased after CMF and FEC, but their variations were not statistically significant with respect to those seen during saline infusion."	1.27	Acute effects of various chemotherapeutic combinations on hypophyseal and pineal hormone secretions in cancer patients. ( Barni, S; Crispino, S; Esposti, D; Esposti, G; Ferri, L; Fumagalli, G; Lissoni, P; Paolorossi, F; Rovelli, F; Tancini, G, 1987)
"Breast cancer, lung carcinoma, and colorectum cancer were the three neoplasms detected in the patients investigated."	1.27	A study on the relationship between the pineal gland and the opioid system in patients with cancer. Preliminary considerations. ( Barni, S; Cattaneo, G; Crispino, S; Esposti, D; Esposti, G; Ferri, L; Lissoni, P; Paolorossi, F; Rovelli, F; Tancini, G, 1988)
"Melatonin was given intramuscularly at a daily dose of 20 mg at 3."	1.27	Clinical study of melatonin in untreatable advanced cancer patients. ( Barni, S; Cattaneo, G; Crispino, S; Esposti, D; Esposti, G; Lissoni, P; Lucini, V; Mariani, M; Paolorossi, F; Tancini, G, 1987)

Research

Studies (326)

Authors

Clinical Trials (16)

Trial Overview

Trial Outcomes

Change in Appetite as Measured by ESAS

Timeframe	Studies, this research(%)	All Research%
pre-1990	19 (5.83)	18.7374
1990's	45 (13.80)	18.2507
2000's	85 (26.07)	29.6817
2010's	109 (33.44)	24.3611
2020's	68 (20.86)	2.80

Authors	Studies
Diamandis, P	1
Wildenhain, J	1
Clarke, ID	1
Sacher, AG	1
Graham, J	1
Bellows, DS	1
Ling, EK	1
Ward, RJ	1
Jamieson, LG	1
Tyers, M	1
Dirks, PB	1
Dolusić, E	1
Larrieu, P	1
Moineaux, L	1
Stroobant, V	1
Pilotte, L	1
Colau, D	1
Pochet, L	1
Van den Eynde, B	1
Masereel, B	1
Wouters, J	1
Frédérick, R	1
Lin, R	1
Elf, S	1
Shan, C	1
Kang, HB	1
Ji, Q	1
Zhou, L	2
Hitosugi, T	1
Zhang, L	2
Zhang, S	1
Seo, JH	1
Xie, J	1
Tucker, M	1
Gu, TL	1
Sudderth, J	1
Jiang, L	1
Mitsche, M	1
DeBerardinis, RJ	1
Wu, S	1
Li, Y	2
Mao, H	1
Chen, PR	1
Wang, D	1
Chen, GZ	1
Hurwitz, SJ	1
Lonial, S	1
Arellano, ML	1
Khoury, HJ	1
Khuri, FR	1
Lee, BH	1
Lei, Q	1
Brat, DJ	1
Ye, K	1
Boggon, TJ	1
He, C	1
Kang, S	1
Fan, J	1
Chen, J	1
Maruta, H	1
Ahn, MR	1
Bastani, S	1
Akbarzadeh, M	3
Rastgar Rezaei, Y	1
Farzane, A	1
Nouri, M	3
Mollapour Sisakht, M	1
Fattahi, A	1
Reiter, RJ	47
Lubas, MM	1
Mandrell, BN	1
Greene, WL	1
Howell, CR	1
Christensen, R	1
Kimberg, CI	1
Li, C	1
Ness, KK	1
Srivastava, DK	1
Hudson, MM	1
Robison, LL	1
Krull, KR	1
Brinkman, TM	1
Wang, Z	2
Liu, Y	1
Musa, AE	4
Sharma, R	6
Rosales-Corral, S	4
Manucha, W	1
Chuffa, LGA	4
Zuccari, DAPC	4
Ashrafizadeh, M	1
Ahmadi, Z	1
Yaribeygi, H	1
Sathyapalan, T	1
Jamialahmadi, T	1
Sahebkar, A	2
Nikolaev, G	1
Robeva, R	1
Konakchieva, R	1
Abdel-Rahman Mohamed, A	1
Khater, SI	1
Metwally, MMM	1
Bin Emran, T	1
Nassan, MA	1
Abd El-Emam, MM	1
Mostafa-Hedeab, G	1
El-Shetry, ES	1
Loh, D	1
Wang, L	1
Wang, C	2
Choi, WS	1
Moslehi, M	1
Moazamiyanfar, R	1
Dakkali, MS	1
Rezaei, S	1
Rastegar-Pouyani, N	1
Jafarzadeh, E	1
Mouludi, K	1
Khodamoradi, E	1
Taeb, S	1
Najafi, M	8
Sadoughi, F	2
Maleki Dana, P	2
Homayoonfal, M	1
Sharifi, M	1
Asemi, Z	5
Targhazeh, N	2
Rahimi, M	1
Qujeq, D	1
Yousefi, T	1
Shahavi, MH	1
Mir, SM	1
Mohammadi, S	1
Heidar, Z	1
Mirzamoradi, M	1
Muscogiuri, G	1
Poggiogalle, E	1
Barrea, L	1
Tarsitano, MG	1
Garifalos, F	1
Liccardi, A	1
Pugliese, G	1
Savastano, S	1
Colao, A	1
Fan, R	1
Bu, X	1
Yang, S	1
Tan, Y	1
Wang, T	1
Chen, H	3
Li, X	2
Hutt, KJ	1
Winship, AL	1
Reiter, R	1
Yousefi, B	4
Dauchy, RT	7
Hill, SM	4
Blask, DE	9
Samanta, S	2
Franco, PIR	3
do Carmo Neto, JR	3
Milhomem, AC	3
Machado, JR	3
Miguel, MP	3
Laborda-Illanes, A	3
Sánchez-Alcoholado, L	3
Castellano-Castillo, D	3
Boutriq, S	3
Plaza-Andrades, I	3
Aranega-Martín, L	3
Peralta-Linero, J	3
Alba, E	3
González-González, A	4
Queipo-Ortuño, MI	3
Cao, M	2
Xu, T	3
Yin, D	2
Anderson, G	3
Rodríguez-Santana, C	1
Florido, J	1
Martínez-Ruiz, L	1
López-Rodríguez, A	1
Acuña-Castroviejo, D	2
Escames, G	1
Slominski, RM	1
Raman, C	1
Chen, JY	1
Slominski, AT	1
Liao, H	1
Li, H	1
Dong, J	1
Song, J	1
Si, H	1
Wang, J	1
Bai, X	1
Mafi, A	1
Keshavarzmotamed, A	1
Hedayati, N	1
Yeganeh Boroujeni, Z	1
Mousavi Dehmordi, R	1
Aarabi, MH	1
Rezaee, M	1
Helmi, YY	1
Papenkordt, N	1
Rennar, G	1
Gbahou, F	1
El-Hady, AK	1
Labani, N	1
Schmidtkunz, K	1
Boettcher, S	1
Jockers, R	1
Abdel-Halim, M	1
Jung, M	1
Zlotos, DP	1
Aghaz, F	1
Asadi, Z	1
Sajadimajd, S	1
Kashfi, K	1
Arkan, E	1
Rahimi, Z	1
Hekmatirad, S	2
Moloudizargari, M	5
Fallah, M	4
Rahimi, A	1
Poortahmasebi, V	1
Asghari, MH	5
Yoon, SL	1
Grundmann, O	1
Xiao, W	1
Xiong, Z	1
Xiong, W	1
Yuan, C	1
Xiao, H	1
Ruan, H	1
Song, Z	1
Bao, L	1
Cao, Q	1
Wang, K	1
Cheng, G	1
Tong, J	1
Hu, W	1
Ru, Z	1
Liu, D	2
Yang, H	1
Zhang, X	2
Chen, K	1
Mortezaee, K	6
Potes, Y	2
Mirtavoos-Mahyari, H	2
Motevaseli, E	3
Shabeeb, D	3
Farhood, B	7
Ma, Q	4
Chen, Y	2
Hooshangi Shayesteh, MR	1
Haghi-Aminjan, H	3
Yennurajalingam, S	1
Carmack, C	1
Balachandran, D	1
Eng, C	1
Lim, B	1
Delgado, M	1
Guzman Gutierrez, D	1
Raznahan, M	1
Park, M	1
Hess, KR	1
Williams, JL	1
Lu, Z	1
Ochoa, J	1
Bruera, E	3
Zakki, SA	1
Muhammad, JS	2
Li, JL	1
Sun, L	1
Li, ML	1
Feng, QW	1
Li, YL	1
Cui, ZG	2
Inadera, H	2
Rorsales-Corral, S	1
de Almeida Chuffa, LG	1
Maroufi, NF	2
Vahedian, V	2
Hemati, S	1
Rashidi, MR	1
Zahedi, M	1
Pouremamali, F	2
Isazadeh, A	2
Taefehshokr, S	1
Hajazimian, S	2
Seraji, N	1
González, A	1
Rueda, N	1
Alonso-González, C	1
Menéndez, JM	1
Martínez-Campa, C	1
Mitola, S	1
Cos, S	1
Ginzac, A	1
Dubois, S	1
Hager, MO	1
Kwiatkowski, F	3
Passildas, J	1
Biau, J	1
Abrial, C	3
Mouret-Reynier, MA	1
Thivat, E	1
Durando, X	1
Ma, Z	1
Xu, L	1
Di, S	1
Li, W	1
Zhang, J	3
Han, J	1
Yan, X	1
Gulbahce-Mutlu, E	1
Baltaci, SB	1
Menevse, E	1
Mogulkoc, R	1
Baltaci, AK	1
Yang, M	1
Li, L	1
Chen, S	1
Li, S	2
Wang, B	2
Zhang, C	1
Yang, L	1
Xin, H	1
Chen, C	3
Xu, X	1
Zhang, Q	1
He, Y	2
Ye, J	1
Socaciu, AI	1
Ionuţ, R	1
Socaciu, MA	1
Ungur, AP	1
Bârsan, M	1
Chiorean, A	1
Socaciu, C	1
Râjnoveanu, AG	1
Rodríguez, C	5
Puente-Moncada, N	2
Sánchez-Sánchez, AM	3
Herrera, F	2
Rodríguez-Blanco, J	3
Duarte-Olivenza, C	1
Turos-Cabal, M	1
Antolín, I	3
Martín, V	4
Li, M	1
Wu, C	1
Yan, D	1
Tsuneyama, K	1
Hatta, H	1
Carvalho, RF	1
Justulin, LA	1
Cury, SS	1
Seiva, FRF	1
Jardim-Perassi, BV	1
Costanzi, E	1
Simioni, C	1
Conti, I	1
Laface, I	1
Varano, G	1
Brenna, C	1
Neri, LM	1
Lawlor, PG	2
McNamara-Kilian, MT	2
MacDonald, AR	2
Momoli, F	2
Tierney, S	2
Lacaze-Masmonteil, N	2
Dasgupta, M	1
Agar, M	2
Pereira, JL	1
Currow, DC	2
Bush, SH	2
Wu, J	1
Bai, Y	1
Wang, Y	1
Ma, J	2
Pourhanifeh, MH	1
Mehrzadi, S	2
Hosseinzadeh, A	1
Moradkhani, F	2
Montaruli, A	1
Castelli, L	1
Mulè, A	1
Scurati, R	1
Esposito, F	1
Galasso, L	1
Roveda, E	1
Maleki, M	1
Khelghati, N	1
Alemi, F	1
Younesi, S	1
Abolhasan, R	1
Bazdar, M	1
Samadi-Kafil, H	1
Jafari-Koulaee, A	1
Bagheri-Nesami, M	1
Talib, WH	2
Alsayed, AR	1
Abuawad, A	1
Daoud, S	1
Mahmod, AI	1
Novais, AA	1
Pourmohammad, P	1
Rashidi, M	1
Faridvand, Y	1
Ghaffari-Novin, M	1
Nejabati, HR	1
Dauchy, EM	1
Tirrell, RP	1
Davidson, LK	1
Sauer, LA	4
Jiang, H	1
Du, K	1
Xie, T	1
Cen, B	1
Yuan, Y	1
Zhou, Y	1
Meng, X	1
Zhang, JJ	1
Xu, DP	1
Li, HB	1
Rosales-Corral, SA	1
Tan, DX	9
Qin, L	1
Yang, SF	2
Xu, K	1
Majidinia, M	2
Sadeghpour, A	1
Khatami, N	1
Zuev, VA	1
Trifonov, NI	1
Linkova, NS	1
Kvetnaia, TV	2
Ballyuzek, MF	1
Mashkova, MV	1
Arutjunyan, AV	2
Duke, VA	1
Jang, H	1
Hong, K	1
Choi, Y	1
Hunter, CM	1
Figueiro, MG	2
Zubidat, AE	1
Haim, A	1
Wojcik, M	1
Krawczyk, M	1
Wojcik, P	1
Cypryk, K	1
Wozniak, LA	1
Proietti, S	2
Cucina, A	2
Minini, M	1
Bizzarri, M	2
Mattox, TW	1
Goradel, NH	3
Negahdari, B	1
Abdollahi, M	3
Markus, RP	1
Fernandes, PA	1
Kinker, GS	1
da Silveira Cruz-Machado, S	1
Marçola, M	1
Hanikoglu, A	1
Kucuksayan, E	1
Akduman, RC	1
Ozben, T	1
Di Bella, G	3
Gualano, L	3
Di Bella, L	4
Ghobadi, E	1
Block, KI	2
Jupp, PW	1
Bjørklund, G	1
Rajib, SA	1
Saffoon, N	1
Pen, JJ	1
Chirumbolo, S	1
Giudice, A	1
Crispo, A	1
Grimaldi, M	1
Polo, A	1
Bimonte, S	1
Capunzo, M	1
Amore, A	1
D'Arena, G	1
Cerino, P	1
Budillon, A	1
Botti, G	1
Costantini, S	1
Montella, M	1
Bondy, SC	2
Campbell, A	1
Rahimifard, M	1
Didari, T	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Multimodal Therapy for the Treatment of Sleep Disturbance in Patients With Cancer[NCT01628029]	Phase 2	68 participants (Actual)	Interventional	2014-01-15	Active, not recruiting
The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study Prior to a Larger Randomized Controlled Trial[NCT02200172]	Phase 2	60 participants (Actual)	Interventional	2014-12-31	Completed
Assessing Quality of Life and the Feasibility of a Nutrition and Pharmacological Algorithm for Oncology Patients With Anorexia[NCT04155008]	Phase 4	1 participants (Actual)	Interventional	2021-03-01	Terminated (stopped due to The trial was closed after 4 months due to slow to accrual. Only 1 participant was enrolled.)
The Traditional Chinese Medicine Department of Xin Qiao Hospital[NCT02619266]	Phase 2/Phase 3	160 participants (Anticipated)	Interventional	2015-12-31	Recruiting
A Randomized Clinical Trial of Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients[NCT00513357]	Phase 3	82 participants (Actual)	Interventional	2006-06-30	Completed
Melatonin, Nightshift Work and DNA Damage (MEND) Study[NCT03945955]	Phase 4	36 participants (Anticipated)	Interventional	2019-07-31	Not yet recruiting
Melatonin for Fatigue and Other Symptoms in Patients With Advanced Cancer[NCT00925899]	Phase 2/Phase 3	72 participants (Actual)	Interventional	2009-10-31	Completed
Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy: A Randomized, add-on Placebo-controlled Clinical Trial[NCT03590197]	Phase 4	104 participants (Actual)	Interventional	2018-08-06	Completed
A Single Center, Open Label Prospective Observational Pilot Study to Evaluate the Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)[NCT05922995]	Early Phase 1	20 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality: A Randomized Placebo Controlled Clinical Trial[NCT00668707]	Phase 3	709 participants (Actual)	Interventional	2007-09-30	Completed
Advanced Integrative Oncology Treatment for Adult and Pediatric Patients With Cancer: A Prospective Outcomes Study[NCT04495790]		500 participants (Anticipated)	Observational [Patient Registry]	2020-05-18	Recruiting
A Pilot, Open-label Study to Evaluate the Effects of a Prostate Health Formulation on Scores Attained From the International Prostate Symptom Score (I-PSS) Questionnaire Among Overall Healthy Male Participants Who Report Lower Urinary Tract Complaints[NCT02886832]		30 participants (Anticipated)	Interventional	2016-09-21	Completed
The Effectiveness of Melatonin in Prevention of Radiation-induced Oral Mucositis[NCT03833570]	Phase 2	40 participants (Actual)	Interventional	2018-01-12	Completed
Assessing the Efficacy of Melatonin on Bone Health in Peri-menopausal Women[NCT01152580]	Phase 1	19 participants (Actual)	Interventional	2008-09-30	Completed
Influence of Radiation Patterns Following Circadian Rhythm Upon Response of Radiotherapy of Uterine Cervical Cancer : Melatonin as a Radiosensitivity and Biological Marker[NCT05511740]		71 participants (Actual)	Interventional	2010-01-31	Completed
Effect of the Administration of Melatonin and Metformin on Glycemic Control, Genotoxicity and Cytotoxicity Markers in Patients With Prediabetes: Pilot Study[NCT03848533]	Phase 2	42 participants (Anticipated)	Interventional	2019-08-22	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Difference in ESAS (Edmonton Symptom Assessment Scale) assessment scores of appetite (symptom) from baseline evaluation [± 3 days] to 4 week evaluation [± 3 days], where the severity at the time of assessment is rated from 0 to 10 on a numerical scale; with 0 meaning that the symptom is absent and 10 that it is the worst possible severity. (NCT00513357)
Timeframe: Baseline and at 4 weeks

Appetite Loss as Measured by the Questionnaire EORTC QLQ-C15-PAL (Groenvold M, Petersen MA, Aaronson NK, et al, Eur J Cancer 42:55-64, 2006)

Intervention	units on a scale (Mean)
Melatonin	-0.83
Placebo	-1.19

"Change from baseline to week one in intervention group minus change from baseline to week one in control group.~Because it was a cross-over trial this was calculated the following way:~Outcomes for arm 1 (melatonin then placebo) were calculated as the difference in mean change scores between week 1 and week 2 (scores for day 7 to day 1-scores for day 17 to day 10). Outcomes for arm 2 (placebo then melatonin) were calculated as the difference in mean change scores between week 2 and week 1 (scores for day 17 to day 10-scores for day 7 to day 1).~Appetite loss was converted to a 0 til 100 scale according to the scoring manual for EORTC QLQ C15-PAL where 100 indicated maximum appetite loss (worst possible).~Note outcome reported for complete compliers" (NCT00925899)
Timeframe: One week

Emotional Function as Measured by the Questionnaire EORTC QLQ-C15-PAL (Groenvold M, Petersen MA, Aaronson NK, et al, Eur J Cancer 42:55-64, 2006)

Intervention	units on a scale (Mean)
Melatonin Then Placebo	-0.8
Placebo Then Melatonin	-3.2

"Change from baseline to week one in intervention group minus change from baseline to week one in control group.~Because it was a cross-over trial this was calculated the following way:~Outcomes for arm 1 (melatonin then placebo) were calculated as the difference in mean change scores between week 1 and week 2 (scores for day 7 to day 1-scores for day 17 to day 10). Outcomes for arm 2 (placebo then melatonin) were calculated as the difference in mean change scores between week 2 and week 1 (scores for day 17 to day 10-scores for day 7 to day 1).~Emotional function was converted to a 0 til 100 scale according to the scoring manual for EORTC QLQ C15-PAL where 100 indicated the best possible emotional function.~Note outcome reported for complete compliers" (NCT00925899)
Timeframe: One week

Fatigue as Measured by the Physical Fatigue Scale in the The Multidimensional Fatigue Inventory (MFI) (Smets EM, Garssen B, Bonke B, et al., J Psychosom Res 39:315-325, 1995)

Intervention	units on a scale (Mean)
Melatonin Then Placebo	-0.6
Placebo Then Melatonin	3.3

"Primary outcome: Change from baseline to week one in intervention group minus change from baseline to week one in control group.~Because it was a cross-over trial this was calculated the following way:~Outcomes for arm 1 (melatonin then placebo) were calculated as the difference in mean change scores between week 1 and week 2 (scores for day 7 to day 1-scores for day 17 to day 10). Outcomes for arm 2 (placebo then melatonin) were calculated as the difference in mean change scores between week 2 and week 1 (scores for day 17 to day 10-scores for day 7 to day 1).~The physical fatigue scale conists of four item each ranging from one to five. The four item were summed and the scae was converted to 0 to 100, where 100 indicated maximum fatigue." (NCT00925899)
Timeframe: One week

General Fatigue Measured by the The Multidimensional Fatigue Inventory (MFI)

Intervention	units on a scale (Mean)
Melatonin Then Placebo	-1.1
Placebo Then Melatonin	-3.9

"Change from baseline to week one in intervention group minus change from baseline to week one in control group.~Because it was a cross-over trial this was calculated the following way:~Outcomes for arm 1 (melatonin then placebo) were calculated as the difference in mean change scores between week 1 and week 2 (scores for day 7 to day 1-scores for day 17 to day 10). Outcomes for arm 2 (placebo then melatonin) were calculated as the difference in mean change scores between week 2 and week 1 (scores for day 17 to day 10-scores for day 7 to day 1).~The general fatigue scale that consits of four items was converted to a 0 til 100 scale where 100 indicated maximum (worst possible) fatigue.~Note outcome reported for complete compliers" (NCT00925899)
Timeframe: One week

Insomnia Measured by the Insomnia Item in the Questionnaire EORTC QLQ-C15-PAL

Intervention	units on a scale (Mean)
Melatonin Then Placebo	-3.2
Placebo Then Melatonin	-2.1

"Primary outcome: Change from baseline to week one in intervention group minus change from baseline to week one in control group.~Because it was a cross-over trial this was calculated the following way:~Outcomes for arm 1 (melatonin then placebo) were calculated as the difference in mean change scores between week 1 and week 2 (scores for day 7 to day 1-scores for day 17 to day 10). Outcomes for arm 2 (placebo then melatonin) were calculated as the difference in mean change scores between week 2 and week 1 (scores for day 17 to day 10-scores for day 7 to day 1).~Insomnia was converted to a 0 til 100 scale according to the scoring manual for EORTC QLQ C15-PAL where 100 indicated maximum insomnia." (NCT00925899)
Timeframe: One week

Pain as Measured by the Questionnaire EORTC QLQ-C15-PAL (Groenvold M, Petersen MA, Aaronson NK, et al, Eur J Cancer 42:55-64, 2006)

Intervention	units on a scale (Mean)
Melatonin Then Placebo	-9.9
Placebo Then Melatonin	-4.6

"Change from baseline to week one in intervention group minus change from baseline to week one in control group.~Because it was a cross-over trial this was calculated the following way:~Outcomes for arm 1 (melatonin then placebo) were calculated as the difference in mean change scores between week 1 and week 2 (scores for day 7 to day 1-scores for day 17 to day 10). Outcomes for arm 2 (placebo then melatonin) were calculated as the difference in mean change scores between week 2 and week 1 (scores for day 17 to day 10-scores for day 7 to day 1).~Pain was converted to a 0 til 100 scale according to the scoring manual for EORTC QLQ C15-PAL where 100 indicated maximum pain.~Note outcome reported for complete compliers" (NCT00925899)
Timeframe: One week

Quality of Life as Measured by the Questionnaire EORTC QLQ-C15-PAL (Groenvold M, Petersen MA, Aaronson NK, et al, Eur J Cancer 42:55-64, 2006)

Intervention	units on a scale (Mean)
Melatonin Then Placebo	0.8
Placebo Then Melatonin	1.9

"Change from baseline to week one in intervention group minus change from baseline to week one in control group.~Because it was a cross-over trial this was calculated the following way:~Outcomes for arm 1 (melatonin then placebo) were calculated as the difference in mean change scores between week 1 and week 2 (scores for day 7 to day 1-scores for day 17 to day 10). Outcomes for arm 2 (placebo then melatonin) were calculated as the difference in mean change scores between week 2 and week 1 (scores for day 17 to day 10-scores for day 7 to day 1).~Quality of Life was converted to a 0 til 100 scale according to the scoring manual for EORTC QLQ C15-PAL where 100 indicated best possible quality of life.~Note outcome reported for complete compliers" (NCT00925899)
Timeframe: One week

Adverse Events (Chemotherapy)

Intervention	units on a scale (Mean)
Melatonin Then Placebo	-0.8
Placebo Then Melatonin	-3.2

Number of participants who experienced an adverse event related to their adjuvant chemotherapy (NCT00668707)
Timeframe: 2 years

Adverse Events (Radiation)

Intervention	Participants (Count of Participants)
Melatonin	44
Placebo	48

Number of participants who experienced an adverse event related to their adjuvant radiation therapy (NCT00668707)
Timeframe: 2 years

Blood Tests to Examine the Effects of Melatonin on the Immune System (Comparison Between Groups)

Intervention	Participants (Count of Participants)
Melatonin	8
Placebo	5

Differences in NK cell cytotoxicity between both arms (NCT00668707)
Timeframe: 6 months

Lung Cancer Recurrence or Mortality - 2 Years

Intervention	Ratio of percent cytotoxicity (Mean)
Melatonin	1.1
Placebo	1.16

Disease-Free survival (DFS) at 2 years post-surgery. DFS is measured by the number of participants in both arms who have experienced a recurrence OR mortality at 2 years. (NCT00668707)
Timeframe: 2 years

Anxiety

Intervention	Participants (Count of Participants)
Melatonin	80
Placebo	85

Measured using the Beck Anxiety Inventory. Scored range from 0-63, where 0 is no anxiety and 63 is the worst possible anxiety. (NCT00668707)
Timeframe: 2 years

Blood Tests to Examine the Effects of Melatonin on the Immune System (Raw Values)

Intervention	Score on a scale of 0-63 (Mean)
	Baseline	2Y
Melatonin	8.2	6.2
Placebo	8.3	6.4

NK cell cytotoxicity changes from baseline to 6 months (NCT00668707)
Timeframe: 6 months

Depression

Intervention	Percent killing of K62 cells (Mean)
	Cytotoxicity (baseline)	Cytotoxicity (6 months)
Melatonin	49.8	49.2
Placebo	42.7	46.4

Measured using the Beck Depression Inventory II. Scores range from 0-63, where 0 is no depression and 63 is the worst possible depression. (NCT00668707)
Timeframe: 2 years

Fatigue

Intervention	Score on a scale of 0-63 (Mean)
	Baseline	2Y
Melatonin	8.1	6.6
Placebo	8.6	7.7

Measured using the Multidimensional Fatigue Inventory 20 (MFI-20) questionnaire. Scores are on a scale of 0-100, where 100 is the best health and 0 is the worst health. (NCT00668707)
Timeframe: 2 years

Lung Cancer Recurrence or Mortality - 5 Years

Intervention	Score on a scale of 0-100 (Least Squares Mean)
	Baseline	1Y	2Y
Melatonin	59.8	61.4	62.7
Placebo	57.0	62.4	63.1

Measured as disease-free survival (DFS) at 5 years. DFS was measured by the incidence of a recurrence OR mortality up to 5 years post-surgery. (NCT00668707)
Timeframe: up to 5 years

Pain Levels

Intervention	Participants (Count of Participants)
	All participants	Early Stage Cancer	Late Stage Cancer
Melatonin	133	109	23
Placebo	130	99	31

Calculated using the Brief Pain Inventory. Each scale ranges from 0-10, where 0 is no pain and 10 is the worst possible pain. (NCT00668707)
Timeframe: 3 months

Quality of Life

Intervention	Score on a scale of 0-10 (Mean)
	Baseline	3 months
Melatonin	2.4	2.3
Placebo	2.3	2.4

Participant-reported quality of life using the European Organization for Research and Treatment of Cancer's Quality of Life Questionnaire C-30 (EORTC QLQ C-30) and Lung Cancer 13 (EORTC QLQ LC13) questionnaires. Scores represent a value from 0-100. Symptom and LC13 scale: 0 represents best health, 100 worst health. Global and functional scales: 100 represents best health, 0 represents worst health. Full scoring algorithms available here: https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf (NCT00668707)
Timeframe: 2 years

Sleep

Intervention	Score on a scale of 0-100 (Least Squares Mean)
	Symptom Scale (Baseline)	Symptom Scale (1Y)	Symptom Scale (2Y)	Functional Scale (Baseline)	Functional Scale (1Y)	Functional Scale (2Y)	Global Scale (Baseline)	Global Scale (1Y)	Global Scale (2Y)	LC13 Scale (Baseline)	LC13 Scale (1Y)	LC13 Scale (2Y)
Melatonin	21.4	18.2	17.3	75.8	79.9	80.2	64.5	69.6	70.7	17.4	17.8	17.1
Placebo	20.3	17.0	15.8	75.5	81.1	80.5	62.7	71.6	72.7	19.0	18.1	17.5

Measured using the Medical Outcomes Study (MOS) Sleep Survey. Scales used were Sleep Adequacy and Sleep problems Index II. Scores are on a scale of 0-100. Sleep Adequacy: 100 represents best health; 0 represents worst health. Problems index: 0 represents best health; 100 represents worst health. (NCT00668707)
Timeframe: 2 years

The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Bone Density in Women After 6 Months, as Compared to Baseline.

Intervention	Score on a scale of 0-100 (Least Squares Mean)
	Sleep Adequacy (Baseline)	Sleep Adequacy (1Y)	Sleep Adequacy (2Y)	Sleep Problems Index II (baseline)	Sleep Problems Index II (1Y)	Sleep Problems Index II (2Y)
Melatonin	56.7	60.9	59.4	32.7	28.0	27.5
Placebo	53.8	61.5	60.5	33.6	27.7	26.9

The mean change in bone mineral density (BMD), represented by T-scores, was assessed by calcaneal ultrasound in women taking melatonin (3 mg) or placebo nightly at baseline and after 6 months. A T-score is a comparison of a subject's BMD to that of a healthy 30 year old female of the same ethnicity. The more negative the T-score, the worse the BMD. Osteoporosis or brittle bone disease is defined as a T-score -2.5 or less. A more negative mean change in a T-score would indicate a worsening of BMD. A more positive mean change in a T-score would indicate an improvement of BMD. (NCT01152580)
Timeframe: Baseline and 6 months

The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Menopause-Specific Quality of Life (MENQOL) Physical Domain Scores in Women After 6 Months, as Compared to Baseline.

Intervention	T-score (Mean)
Sugar Pill	-0.02
Melatonin	0.05

"Menopause-Specific Quality of Life (MENQOL) questionnaires were administered to women at baseline and after 6 months of taking placebo or melatonin nightly. The MENQOL is a validated questionnaire that measures 4 domains of menopause quality of life in women: physical, vasomotor, psychosocial and sexual with each domain having a scale of not bothered (score 0) or bothered ranging from 1(not too bothered) to 6 (really bothered). A more negative mean change for each of the MENQOL domain scores indicates an improvement of these symptoms and a more positive value a worsening of symptoms." (NCT01152580)
Timeframe: Baseline and 6 mos

The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Menopause-Specific Quality of Life (MENQOL) Psychosocial Domain Scores in Women After 6 Months, as Compared to Baseline.

Intervention	units on a scale (Mean)
Sugar Pill	0.1
Melatonin	-0.6

The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Menopause-Specific Quality of Life (MENQOL) Sexual Domain Scores in Women After 6 Months, as Compared to Baseline.

Intervention	units on a scale (Mean)
Sugar Pill	-0.2
Melatonin	-0.4

The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Menopause-Specific Quality of Life (MENQOL) Vasomotor Domain Scores in Women After 6 Months, as Compared to Baseline.

Intervention	units on a scale (Mean)
Sugar Pill	-0.7
Melatonin	-0.4

The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Serum Osteocalcin (OC) Levels in Women After 6 Months, as Compared to Baseline

Intervention	units on a scale (Mean)
Sugar Pill	-0.2
Melatonin	0.4

Osteocalcin is a measure of osteoblast activity because it is secreted from osteoblasts. Osteocalcin levels were measured in the serum of women at baseline and after 6 months of taking placebo or melatonin (3 mg) and the data are reported as ng/mL. Osteoblasts are bone-forming cells so a more positive mean change in osteoblast activity over time (6 months - baseline) could indicate an improvement in bone mineral density. A more negative mean change in osteocalcin levels over time (6 months - baseline) could indicate a worsening of bone mineral density. (NCT01152580)
Timeframe: Baseline and 6 months

The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Serum Type-1 Collagen Cross-linked N-telopeptide (NTX) Levels in Women After 6 Months, as Compared to Baseline.

Intervention	ng/mL (Mean)
Sugar Pill	-0.6
Melatonin	1.83

Type-1 collagen cross-linked N-telopeptide (NTX) levels were measured in the serum of women at baseline and after taking placebo or melatonin (3 mg) nightly for 6 months. NTX, reported as bone collagen equivalents (BCE), is released from bone due to the actions of osteoclasts or bone breakdown cells. A more positive mean change in NTX levels (6 months - baseline) could result in a worsening of bone mineral density due to an increase in bone breakdown whereas a more negative mean change in NTX levels could result in an improvement in bone mineral density due to a decrease in bone breakdown. (NCT01152580)
Timeframe: Baseline and 6 months

The Effect of Melatonin (3 mg) or Placebo on the Mean Change in the Pittsburgh Sleep Quality Index (PSQI) in Women After 6 Months, as Compared to Baseline.

Intervention	nM BCE (Mean)
Sugar Pill	-0.36
Melatonin	-0.32

"Pittsburgh Sleep Quality Index (PSQI) Questionnaire is a validated questionnaire that assesses the quality and quantity of sleep and sleep disorders.This survey is designed to identify good and poor sleepers and has a score scale that ranges from 0-21 with 0 being good quality of sleep and 21 being poor quality of sleep and/or indicating as having a sleep disorder. A more positive mean change in the PSQI over time indicates a worsening of sleep. A more negative mean change in the PSQI over time indicates an improvement in sleep." (NCT01152580)
Timeframe: Baseline and 6 months

Article	Year
A randomized double-blind placebo-controlled trial of the effectiveness of melatonin on neurocognition and sleep in survivors of childhood cancer. Pediatric blood & cancer, 2022, Volume: 69, Issue:1 Topics: Adult; Cancer Survivors; Child; Double-Blind Method; Humans; Melatonin; Neoplasms; Sleep; Survivors	2022
A randomized double-blind placebo-controlled trial of the effectiveness of melatonin on neurocognition and sleep in survivors of childhood cancer. Pediatric blood & cancer, 2022, Volume: 69, Issue:1 Topics: Adult; Cancer Survivors; Child; Double-Blind Method; Humans; Melatonin; Neoplasms; Sleep; Survivors	2022
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. Science & sports, 2023, Apr-04 Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp	2023
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. Science & sports, 2023, Apr-04 Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp	2023
Melatonin to prevent delirium in patients with advanced cancer: a double blind, parallel, randomized, controlled, feasibility trial. BMC palliative care, 2020, Oct-21, Volume: 19, Issue:1 Topics: Aged; Delirium; Double-Blind Method; Feasibility Studies; Female; Humans; Male; Melatonin; Middle Ag	2020
Melatonin to prevent delirium in patients with advanced cancer: a double blind, parallel, randomized, controlled, feasibility trial. BMC palliative care, 2020, Oct-21, Volume: 19, Issue:1 Topics: Aged; Delirium; Double-Blind Method; Feasibility Studies; Female; Humans; Male; Melatonin; Middle Ag	2020
Phase I dose-finding study for melatonin in pediatric oncology patients with relapsed solid tumors. Pediatric blood & cancer, 2019, Volume: 66, Issue:6 Topics: Adolescent; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Child; Child, Pr	2019
Phase I dose-finding study for melatonin in pediatric oncology patients with relapsed solid tumors. Pediatric blood & cancer, 2019, Volume: 66, Issue:6 Topics: Adolescent; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Child; Child, Pr	2019
Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-01, Volume: 31, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Appetite; Body Weight; Cachexia; Depression; Double-Bl	2013
Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-01, Volume: 31, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Appetite; Body Weight; Cachexia; Depression; Double-Bl	2013
Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-01, Volume: 31, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Appetite; Body Weight; Cachexia; Depression; Double-Bl	2013
Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-01, Volume: 31, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Appetite; Body Weight; Cachexia; Depression; Double-Bl	2013
Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-01, Volume: 31, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Appetite; Body Weight; Cachexia; Depression; Double-Bl	2013
Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-01, Volume: 31, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Appetite; Body Weight; Cachexia; Depression; Double-Bl	2013
Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-01, Volume: 31, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Appetite; Body Weight; Cachexia; Depression; Double-Bl	2013
Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-01, Volume: 31, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Appetite; Body Weight; Cachexia; Depression; Double-Bl	2013
Cancer as the main aging factor for humans: the fundamental role of 5-methoxy-tryptamine in reversal of cancer-induced aging processes in metabolic and immune reactions by non-melatonin pineal hormones. Current aging science, 2012, Volume: 5, Issue:3 Topics: 5-Methoxytryptamine; Administration, Oral; Age Factors; Aging; Antineoplastic Combined Chemotherapy	2012
Cancer as the main aging factor for humans: the fundamental role of 5-methoxy-tryptamine in reversal of cancer-induced aging processes in metabolic and immune reactions by non-melatonin pineal hormones. Current aging science, 2012, Volume: 5, Issue:3 Topics: 5-Methoxytryptamine; Administration, Oral; Age Factors; Aging; Antineoplastic Combined Chemotherapy	2012
Individual variations in serum melatonin levels through time: implications for epidemiologic studies. PloS one, 2013, Volume: 8, Issue:12 Topics: Aged; Body Mass Index; Circadian Rhythm; Humans; Longitudinal Studies; Male; Melatonin; Middle Aged;	2013
Individual variations in serum melatonin levels through time: implications for epidemiologic studies. PloS one, 2013, Volume: 8, Issue:12 Topics: Aged; Body Mass Index; Circadian Rhythm; Humans; Longitudinal Studies; Male; Melatonin; Middle Aged;	2013
Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double-blind placebo-controlled crossover trial. Cancer, 2015, Oct-15, Volume: 121, Issue:20 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Double-Blind Method; Drug	2015
Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double-blind placebo-controlled crossover trial. Cancer, 2015, Oct-15, Volume: 121, Issue:20 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Double-Blind Method; Drug	2015
The preventative role of exogenous melatonin administration to patients with advanced cancer who are at risk of delirium: study protocol for a randomized controlled trial. Trials, 2016, 08-11, Volume: 17 Topics: Central Nervous System Agents; Clinical Protocols; Dementia; Double-Blind Method; Feasibility Studie	2016
The preventative role of exogenous melatonin administration to patients with advanced cancer who are at risk of delirium: study protocol for a randomized controlled trial. Trials, 2016, 08-11, Volume: 17 Topics: Central Nervous System Agents; Clinical Protocols; Dementia; Double-Blind Method; Feasibility Studie	2016
Prevention of melatonin suppression by nocturnal lighting: relevance to cancer. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2007, Volume: 16, Issue:4 Topics: Adult; Animals; Asian People; Circadian Rhythm; Humans; Lighting; Male; Melatonin; Neoplasms	2007
Prevention of melatonin suppression by nocturnal lighting: relevance to cancer. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2007, Volume: 16, Issue:4 Topics: Adult; Animals; Asian People; Circadian Rhythm; Humans; Lighting; Male; Melatonin; Neoplasms	2007
A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1995, Volume: 3, Issue:3 Topics: Administration, Oral; Adult; Aged; Drug Therapy, Combination; Female; Hospice Care; Humans; Immunoth	1995
A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1995, Volume: 3, Issue:3 Topics: Administration, Oral; Adult; Aged; Drug Therapy, Combination; Female; Hospice Care; Humans; Immunoth	1995
A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. British journal of cancer, 1994, Volume: 69, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colorec	1994
A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. British journal of cancer, 1994, Volume: 69, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colorec	1994
Modulation of tumor necrosis factor-alpha (TNF-alpha) toxicity by the pineal hormone melatonin (MLT) in metastatic solid tumor patients. Annals of the New York Academy of Sciences, 1995, Sep-30, Volume: 768 Topics: Adult; Aged; Female; Humans; Immunotherapy; Male; Melatonin; Middle Aged; Neoplasms; Pineal Gland; R	1995
Modulation of tumor necrosis factor-alpha (TNF-alpha) toxicity by the pineal hormone melatonin (MLT) in metastatic solid tumor patients. Annals of the New York Academy of Sciences, 1995, Sep-30, Volume: 768 Topics: Adult; Aged; Female; Humans; Immunotherapy; Male; Melatonin; Middle Aged; Neoplasms; Pineal Gland; R	1995
Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1996, Volume: 4, Issue:4 Topics: Administration, Oral; Adult; Aged; Cytokines; Drug Therapy, Combination; Female; Humans; Hypotension	1996
Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1996, Volume: 4, Issue:4 Topics: Administration, Oral; Adult; Aged; Cytokines; Drug Therapy, Combination; Female; Humans; Hypotension	1996
[Melatonin. Hormone or wonder drug?]. Medizinische Monatsschrift fur Pharmazeuten, 1996, Volume: 19, Issue:3 Topics: Adult; Aged; Aging; Alzheimer Disease; Animals; Circadian Rhythm; Depressive Disorder; Humans; Melat	1996
[Melatonin. Hormone or wonder drug?]. Medizinische Monatsschrift fur Pharmazeuten, 1996, Volume: 19, Issue:3 Topics: Adult; Aged; Aging; Alzheimer Disease; Animals; Circadian Rhythm; Depressive Disorder; Humans; Melat	1996
A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients. British journal of cancer, 1996, Volume: 74, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap	1996
A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients. British journal of cancer, 1996, Volume: 74, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap	1996
Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1997, Volume: 5, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Dise	1997
Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1997, Volume: 5, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Dise	1997
Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. Natural immunity, 1998, Volume: 16, Issue:1 Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aloe; Brain Neoplasms; Breast Neoplasms; Drug Thera	1998
Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. Natural immunity, 1998, Volume: 16, Issue:1 Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aloe; Brain Neoplasms; Breast Neoplasms; Drug Thera	1998
Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): results of phase II trials in Italy. Italian Study Group for the Di Bella Multitherapy Trails. BMJ (Clinical research ed.), 1999, Jan-23, Volume: 318, Issue:7178 Topics: Antineoplastic Combined Chemotherapy Protocols; Bromocriptine; Complementary Therapies; Female; Huma	1999
Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): results of phase II trials in Italy. Italian Study Group for the Di Bella Multitherapy Trails. BMJ (Clinical research ed.), 1999, Jan-23, Volume: 318, Issue:7178 Topics: Antineoplastic Combined Chemotherapy Protocols; Bromocriptine; Complementary Therapies; Female; Huma	1999
Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms. Annals of the New York Academy of Sciences, 2000, Volume: 917 Topics: 5-Methoxytryptamine; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Indoles;	2000
Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms. Annals of the New York Academy of Sciences, 2000, Volume: 917 Topics: 5-Methoxytryptamine; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Indoles;	2000
Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia. Journal of pineal research, 2001, Volume: 30, Issue:2 Topics: 5-Methoxytryptamine; Adult; Aged; Blood Platelets; Drug Therapy, Combination; Female; Hematopoiesis;	2001
Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia. Journal of pineal research, 2001, Volume: 30, Issue:2 Topics: 5-Methoxytryptamine; Adult; Aged; Blood Platelets; Drug Therapy, Combination; Female; Hematopoiesis;	2001
Is there a role for melatonin in supportive care? Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2002, Volume: 10, Issue:2 Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as To	2002
Is there a role for melatonin in supportive care? Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2002, Volume: 10, Issue:2 Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as To	2002
Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. Oncology, 1991, Volume: 48, Issue:6 Topics: Adult; Aged; Female; Humans; Male; Melatonin; Middle Aged; Neoplasms	1991
Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. Oncology, 1991, Volume: 48, Issue:6 Topics: Adult; Aged; Female; Humans; Male; Melatonin; Middle Aged; Neoplasms	1991

melatonin and Neoplasms